JAK2 and acquired polycythemia vera: Initial molecular testing for common mutations including JAK2 (V617F, exon 12, exon 13 mutations) yielded normal results, reducing the likelihood of polycythemia vera and other acquired myeloproliferative disorders, though rare variants cannot be excluded.